Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus [TA151]

Measuring the use of this guidance

Recommendation: 1.1

"Continuous subcutaneous insulin infusion (CSII or 'insulin pump') therapy is recommended as a treatment option for adults and children 12 years and older with type 1 diabetes mellitus provided that: attempts to achieve target haemoglobin A1c (HbA1c) levels with multiple daily injections (MDIs) result in the person experiencing disabling hypoglycaemia. For the purpose of this guidance, disabling hypoglycaemia is defined as the repeated and unpredictable occurrence of hypoglycaemia that results in persistent anxiety about recurrence and is associated with a significant adverse effect on quality of life or HbA1c levels have remained high (that is, at 8.5% [69 mmol/mol] or above) on MDI therapy (including, if appropriate, the use of long-acting insulin analogues) despite a high level of care."

What was measured: Proportion of people with type 1 diabetes attending specialist services who are being treated with an insulin pump.

Data collection end: March 2016

12.2%

Area covered:	England
Source:	NHS Benchmarking Network. Older People’s Care in Acute Settings Benchmarking Report.

What was measured: Percentage of people with type 1 diabetes attending specialist services who are being treated with an insulin pump.

Data collection end: March 2016

15.3%

Data collection end: March 2017

15.6%

Area covered:	England
Source:	NHS Digital. National diabetes insulin pump audit.

What was measured: "Continuous subcutaneous insulin infusion (CSII or 'insulin pump') therapy is recommended as a treatment option for adults and children 12 years and older with type 1 diabetes mellitus provided that: attempts to achieve target haemoglobin A1c (HbA1c) levels with multiple daily injections (MDIs) result in the person experiencing disabling hypoglycaemia. For the purpose of this guidance, disabling hypoglycaemia is defined as the repeated and unpredictable occurrence of hypoglycaemia that results in persistent anxiety about recurrence and is associated with a significant adverse effect on quality of life or HbA1c levels have remained high (that is, at 8.5% [69 mmol/mol] or above) on MDI therapy (including, if appropriate, the use of long-acting insulin analogues) despite a high level of care."

Data collection end: March 2018

17.7%

Area covered:	England
Source:	NHS Digital. National diabetes insulin pump audit.

Return to TA151 Overview